Third STOCK OPTION AGREEMENTThird Stock Option Agreement • March 13th, 2017 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • Nevada
This Third Stock Option Agreement (“Agreement”) is made as of the 10th day of March, 2017 by and between PharmaCyte Biotech, Inc. (“Company”) and Carlos A. Trujillo (“Participant”).
AMENDMENT NO. 2 TO EXECUTIVE COMPENSATION AGREEMENTFourth Stock Option Agreement • March 13th, 2017 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • Nevada
This Amendment No. 2 to Executive Compensation Agreement (“Amendment No. 2”), dated as of March 10, 2017, and effective as of January 1, 2017, is made by and between PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), and Kenneth L. Waggoner (“Executive”). The Company and the Executive are each referred to in this Amendment No. 2 as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment No. 2 shall have the meanings given to them in the Executive Compensation Agreement defined below.
FOURTH STOCK OPTION AGREEMENTFourth Stock Option Agreement • March 13th, 2017 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • Nevada
This Fourth Stock Option Agreement (“Agreement”) is made as of the 10th day of March, 2017 by and between PharmaCyte Biotech, Inc. (“Company”) and Gerald W. Crabtree (“Participant”).
VIA EMAIL ONLY March 10, 2017 Thomas Liquard Larchmont, NY 10538PharmaCyte Biotech, Inc. • March 13th, 2017 • Medicinal chemicals & botanical products
This letter shall constitute Amendment No. 1 to Director Offer Letter (“Agreement”) between you and PharmaCyte Biotech, Inc. (“Company”) dated April 20, 2015 and effective April 1, 2015 (“Effective Date”) relating to your service to the Company as a member of our Board of Directors (“Board”).
AMENDMENT No. 2 TO executive Compensation AGREEMENTExecutive Compensation Agreement • March 13th, 2017 • PharmaCyte Biotech, Inc. • Medicinal chemicals & botanical products • Nevada
This Amendment No. 2 to Executive Compensation Agreement (“Amendment No. 2”) dated as of March 10, 2017, is made by and between PharmaCyte Biotech, Inc., a Nevada corporation (“Company”), and Carlos A. Trujillo (“Executive”). The Company and the Executive are each referred to in this Amendment No. 2 as a “Party” and collectively as the “Parties.” Capitalized terms used but not defined in this Amendment No. 2 shall have the meanings given to them in the Executive Compensation Agreement defined below.
